» Articles » PMID: 32550060

Focal Active Colitis Presented With Chronic Diarrhea

Overview
Journal Cureus
Date 2020 Jun 19
PMID 32550060
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

There are various etiologies of colonic injury and inflammation. The most commonly described colitides in clinical practice are associated with infection, inflammatory bowel disease, ischemia, radiation and medications. The colonic wall has a limited set of responses to different types of injury; therefore, there is overlap between many of these disorders. Focal active colitis is characterized by isolated neutrophilic cryptitis with the background mucosa displaying normal crypt architecture. This inflammatory pattern can be easily unnoticed by pathologists because on low-power examination the mucosa may have almost normal appearance. General practitioners also may not be familiar with this term, underlying etiologies, associated risk factors, course, available therapies and follow up.  We present a case of an 82-year-old female with chronic diarrhea and weight loss. She had a negative infectious workup and normal radiology series. She subsequently underwent endoscopic evaluation in lieu of persistent and debilitating symptoms which revealed nonspecific macroscopic findings with pathology noting focal active colitis. She was empirically treated with a 14-day course of Xifaxan and responded well to management with almost complete resolution of her symptoms and no recurrence on six-month follow-up.

Citing Articles

Focal Active Colitis: What Are Its Clinical Implications? A Narrative Review.

Sinagra E, Mandarino F, Maida M, Cabibi D, Rossi F, Raimondo D Biomedicines. 2023; 11(10).

PMID: 37893005 PMC: 10604212. DOI: 10.3390/biomedicines11102631.

References
1.
Ozdil K, Sahin A, Calhan T, Kahraman R, Nigdelioglu A, Akyuz U . The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome. BMC Gastroenterol. 2011; 11:96. PMC: 3178529. DOI: 10.1186/1471-230X-11-96. View

2.
Gionchetti P, Rizzello F, Morselli C, Romagnoli R, Campieri M . Management of inflammatory bowel disease: does rifaximin offer any promise?. Chemotherapy. 2005; 51 Suppl 1:96-102. DOI: 10.1159/000081995. View

3.
Schneider E, Havens J, Scott M, Goldblum J, Greenson J, Shaffer R . Molecular diagnosis of Campylobacter jejuni infection in cases of focal active colitis. Am J Surg Pathol. 2006; 30(6):782-5. DOI: 10.1097/00000478-200606000-00017. View

4.
Su C, Aberra F, Lichtenstein G . Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology. Gastroenterol Hepatol (N Y). 2017; 2(3):186-197. PMC: 5335639. View

5.
Osmond A, Ashok D, Francoeur C, Miller M, Walsh J . Is focal active colitis of greater clinical significance in pediatric patients? A retrospective review of 68 cases with clinical correlation. Hum Pathol. 2018; 74:164-169. DOI: 10.1016/j.humpath.2018.01.012. View